article thumbnail

Partnering for success in early phase clinical development

BioPharma Drive: Drug Pricing

Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.

article thumbnail

Centers of excellence or product-centric BizDevOps managed services?

BioPharma Drive: Drug Pricing

As novel therapeutics become more complex — and costly — to bring to market, drug developers are looking to unified clinical development platforms to streamline operations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Harnessing AI and Real-World Data: The Future of Clinical Development

PPD

Our comprehensive approach, integrating various aspects of drug development, such as clinical development, post-approval activities and market access, ensures optimal utilization of tools and strategies. Ready to learn more about convergence of real-world data and technology for clinical trials?

article thumbnail

Carl Sailer on AI, market trends, and strategic planning in biotech

Fierce BioTech

Carl Sailer is Vice President of Full Service Solutions at Syneos Health®, a leading fully integrated biopharmaceutical solutions organization providing clinical development and commercialization s | In this conversation with Fierce Biotech, we explore the ever-evolving biotech landscape.

article thumbnail

Market Insights: What’s Driving the Shift Toward FSP Models in Clinical Development?

Fierce BioTech

As advancements in medical science progress, clinical research and development (R&D) are subject to more sophisticated and complex study designs and protocols that require precise global coordi | Market Insights: What’s Driving the Shift Toward FSP Models in Clinical Development?

article thumbnail

Why early market access planning is crucial in CGT commercial strategy

Fierce BioTech

Experts recommend that CGT manufacturers proactively design a comprehensive market access strategy early in clinical development and commercial planning timelines, ideally more than three years pri | CGT companies should consider developing a market access strategy early in clinical development, ideally more than three years prior to launch.

article thumbnail

Navigating the Clinical Development Landscape: Insights for Success in 2024

Cytel

After explosive and frenetic activity in the clinical trial industry during the COVID era, the past two years have seen challenging market dynamics and a drop-off in activity. Every one of us working in clinical development has felt this slowdown, but as we begin 2024, there is reason for optimism.